Schistosomiasis
Author(s)
Bibliographic Information
Schistosomiasis
(World class parasites / series editors, Samuel J. Black, J. Richard Seed, v. 10)
Springer, c2005
Available at 2 libraries
  Aomori
  Iwate
  Miyagi
  Akita
  Yamagata
  Fukushima
  Ibaraki
  Tochigi
  Gunma
  Saitama
  Chiba
  Tokyo
  Kanagawa
  Niigata
  Toyama
  Ishikawa
  Fukui
  Yamanashi
  Nagano
  Gifu
  Shizuoka
  Aichi
  Mie
  Shiga
  Kyoto
  Osaka
  Hyogo
  Nara
  Wakayama
  Tottori
  Shimane
  Okayama
  Hiroshima
  Yamaguchi
  Tokushima
  Kagawa
  Ehime
  Kochi
  Fukuoka
  Saga
  Nagasaki
  Kumamoto
  Oita
  Miyazaki
  Kagoshima
  Okinawa
  Korea
  China
  Thailand
  United Kingdom
  Germany
  Switzerland
  France
  Belgium
  Netherlands
  Sweden
  Norway
  United States of America
Note
Includes bibliographical references and index
HTTP:URL=http://www.loc.gov/catdir/enhancements/fy0663/2004058995-d.html Information=Publisher description
HTTP:URL=http://www.loc.gov/catdir/enhancements/fy0819/2004058995-t.html Information=Table of contents only
Description and Table of Contents
Description
Human schistosomiasis is a disease with a rich and well-documented past, and every expectation of an unfortunately long future. These infections were known to the ancient Egyptians and their transmission shows little evidence of slowing down, globally. The good news is that field applicable, and increasingly affordable, chemotherapy has been available for almost 25 years. Using chemotherapy and other means of control, some countries have decreased transmission and made excellent headway against morbidity. The bad news is that the public health problems caused by schistosomiasis are still with us, with the estimated number of cases of schistosomiasis, while shifting geographically, remaining approximately 200 million for the last 30 years. In fact, with the development of field usable ultrasound technology and meta-analyses performed on existing data, there is a new appreciation for the extent of non-lethal morbidity associated with these infections. While the percentage of individuals with severe hepatosplenic disease remains below 10%, recent reassessments of morbidity associated with schistosomiasis indicate that the prevelance of symptoms and the cost in diability-adjusted life years is much greater than was previously, commonly appreciated (Van der Werf, M. J. , et al. 2003, Acta Tropica 86:125-139; Charles H. King, personnel communication). Strong impetus for addressing these issues is provided by the World Health Assembly's recently passed Resolution 54. 19, which calls for efforts to reduce morbidity caused by schistosomiasis and soil-transmitted helminths in school-aged children, largely through chemotherapy campaigns.
Table of Contents
Schistosomes and Their Snail Hosts.- Schistosome Retrotransposons.- Gender-specific Biology of Schistosoma mansoni.- Schistosoma Genomics.- Vaccine Development.- The Surface of Schistosomes within the Vertebrate Host.- The Application of DNA Microarrays in the Functional Genomic Study of Schistosome/Host Biology.- The Initiation of Host Immune Responses to Schistosome Egg Antigens.- Immunopathology in Experimental Schistosomiasis.- Immunological and other Factors Affecting Hepatosplenic Schistosomiasis mansoni in Man.- Pathways to Improved, Sustainable Morbidity Control and Prevention of Schistosomiasis in the People's Republic of China.- Host Genetics and Schistosomiasis.- Current and Future Anti-schistosomal Drugs.- Pubic Health Strategies for Schistosomiasis Control.- Schistosomiasis: Are We Ready for a Coordinated Research and Public Health Agenda?- Index.
by "Nielsen BookData"